Thesis Recent pricing pressures and increased competition in the plasma-derived therapy market have raised concerns about margin sustainability.
★ Analysts see FY2027 revenue reaching $8.3B — +6.0% growth in a single year.
What Moves the Stock 01 Changes in plasma collection volumes, particularly in the U.S. and Europe 02 Regulatory approvals for new therapies or indications 03 Pricing adjustments in response to market dynamics 04 Market demand for immunoglobulin therapies 05 Plasma-derived therapies (approximately 70% of total revenue) 06 Diagnostic products (approximately 20% of total revenue) 07 Other healthcare products (approximately 10% of total revenue) 08 Growing demand for plasma-derived therapies due to an aging population 10.0 10.7 11.5 12.2 12.9 11.76 GIFLF Daily 11.76 Apr '26 May '26 Jul '26 Aug '26
My Notes "Management noted, 'While demand remains strong, we are facing unprecedented pricing pressures that could impact our margins.'" Moat: Grifols benefits from a strong brand reputation and established relationships with healthcare providers… value - Investors may be drawn to Grifols due to its low valuation metrics (P/S of 0.8x) and strong cash flow generation. Rising interest rates may increase Grifols' financing costs, particularly given its high debt-to-equity ratio of 1.77… Watch on earnings: Plasma collection volumes, Gross margin percentage, Operating cash flow growth. One Sentence Summary: Grifols: the story is balanced — changes in plasma collection volumes, particularly in the u.s.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.